Clinical Trial Update: Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study

View source ↗

Summary

A Swedish cohort study reports on treatment patterns and outcomes for patients with Hemophilia A or Hemophilia B treated with Benefix or Refacto/Refacto AF.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)
• Refacto (Factor VIII, recombinant)
• Refacto AF (Factor VIII, recombinant)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A, Hemophilia B | Status: COMPLETED | Results posted: 2019-05-03